{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:20:14Z","timestamp":1777418414673,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2003,6]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>The oxazolidinone class of antimicrobials has demonstrated remarkable activity against gram-positive cocci. Linezolid has proven to be a first-line therapeutic option for vancomycin-resistant strains. Linezolid clinical trial results and subsequent published case reports cite rare resistance emerging in patients receiving prolonged therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To report the initial linezolid-resistant organisms from cases obtained through the SENTRY Antimicrobial Surveillance Program, after screening &gt;40 000 gram-positive cocci without resistance between 1998 and 2000.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>During 2001\u20132002, 8 resistant strains (from 8 different patients) located in 6 states from 7 different participating SENTRY institutions in the US were identified among bloodstream, respiratory, skin and soft tissue, and urinary tract infection isolates of Enterococcus faecalis, Enterococcus faecium, Staphylococcus epidermidis, and Streptococcus oralis. Resistance was detected by reference broth microdilution methods and confirmed by identical results using Etest (AB BIODISK, Solna, Sweden) and the standardized disk diffusion method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Minimum inhibitory concentration (MIC) and disk diffusion tests showed elevated MICs (\u22658 \u03bcg\/mL) and small inhibitory zone diameters (\u226415 mm) for all strains to both linezolid and the investigational oxazolidinone AZD2563. Vancomycin resistance was detected in 2 of the 8 linezolid-resistant strains. All enterococci and the viridans-group streptococcus ( S. oralis) strain showed resistance to erythromycin. E. faecium strains were resistant to penicillins, but susceptible to quinupristin\/dalfopristin. Only 3 of the patients had previously received the drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Linezolid resistance remains rare, with only 8 isolates among 9833 (0.08%) monitored isolates identified between January 1, 2001, and June 30, 2002. Resistance, however, was no longer limited to enterococci. Clinical laboratories should test linezolid more widely to detect emerging resistance, especially for patients receiving oxazolidinone therapy. Longitudinal surveillance programs are warranted to detect a trend in the development of resistance, determine the molecular mechanism of resistance, and recommend alternative therapies or epidemiologic interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1c437","type":"journal-article","created":{"date-parts":[[2003,4,17]],"date-time":"2003-04-17T12:40:56Z","timestamp":1050583256000},"page":"769-774","source":"Crossref","is-referenced-by-count":123,"title":["Linezolid Resistance since 2001: SENTRY Antimicrobial Surveillance Program"],"prefix":"10.1177","volume":"37","author":[{"given":"Alan H","family":"Mutnick","sequence":"first","affiliation":[{"name":"Alan H Mutnick PharmD, Director\/Pharmacology, The JONES Group\/JMI Laboratories, North Liberty, IA; Adjunct Associate Professor, College of Pharmacy, University of Iowa, Iowa City, IA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Enne","sequence":"additional","affiliation":[{"name":"Victoria Enne PhD, Postdoctoral Research Assistant, University of Bristol, Bristol, England"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N","family":"Jones","sequence":"additional","affiliation":[{"name":"Ronald N Jones MD, Director\/CEO, The JONES Group\/JMI Laboratories; Adjunct Professor of Medicine, School of Medicine, Tufts University, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2003,6,1]]},"reference":[{"key":"bibr1-aph.1C437","first-page":"597","volume":"42","author":"Nosocomial enterococci resistant to vancomycin \u2014 United States, 1989\u20131993","year":"1993","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"bibr2-aph.1C437","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(02)00371-1"},{"key":"bibr3-aph.1C437","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04376-2"},{"key":"bibr4-aph.1C437","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05410-1"},{"key":"bibr5-aph.1C437","unstructured":"Zurenko GE, Todd WM, Hafkin B, Myers B, Kauffman C, Bock J. Development of linezolid-resistant\n                      Enterococcus faecium\n                      in two compassionate use program patients treated with linezolid (abstract 848). In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, Sept 17\u201320, 2000: 118."},{"key":"bibr6-aph.1C437","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(01)00333-9"},{"key":"bibr7-aph.1C437","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200203143461121"},{"key":"bibr8-aph.1C437","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.7.2154-2156.2001"},{"key":"bibr9-aph.1C437","doi-asserted-by":"publisher","DOI":"10.1086\/320184"},{"key":"bibr10-aph.1C437","doi-asserted-by":"publisher","DOI":"10.1086\/320181"},{"key":"bibr11-aph.1C437","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.11.4298-4299.2000"},{"key":"bibr12-aph.1C437","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.6.783"},{"key":"bibr13-aph.1C437","volume-title":"Document M7-A5","author":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","year":"2000"},{"key":"bibr14-aph.1C437","volume-title":"Document M100-S12","year":"2002"},{"key":"bibr15-aph.1C437","volume-title":"Performance standards for antimicrobial disk susceptibility tests. Document M2-A7","year":"2002"},{"key":"bibr16-aph.1C437","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.10.3334-3336.2002"},{"key":"bibr17-aph.1C437","unstructured":"Errors in health care: a leading cause of death and injury. In: Kohn LT, Corrigan JM, Donaldson MS, eds. Too err is human: building a safer health system. Institute of Medicine Report. Chapter 2, errors in health care: a leading cause of death and injury. Washington, DC: National Academy Press, 1999: 22\u201341. www.nap.edu\/html\/to_err_is_human\/ (accessed 2003 Jan 16)."},{"key":"bibr18-aph.1C437","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a113988"},{"key":"bibr19-aph.1C437","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a113990"},{"key":"bibr20-aph.1C437","first-page":"577","volume-title":"Hospital infections","author":"Martone WJ","year":"1992"},{"key":"bibr21-aph.1C437","first-page":"27","volume":"87","author":"Kuehm SL","year":"1990","journal-title":"NJ Med"},{"key":"bibr22-aph.1C437","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A333"},{"key":"bibr23-aph.1C437","unstructured":"ASM Task Force, 1994: Discussion paper:\n                      a proposed framework for evaluating and assuring the human safety of the microbial effects of antimicrobial new animal drugs intended for use in food-producing animals.\n                      Food and Drug Administration (FDA), Department of Health and Human Services (HHS) Docket No. 98D\u20131146. www.asmusa.org\/pasrc\/fdaframework.htm (accessed 2003 Apr 9)."},{"key":"bibr24-aph.1C437","unstructured":"EU Conference, 2001; Visby, Sweden; June 13\u201315, 2001: progress report on antimicrobial resistance. www.fedesa.be\/Antibio\/Visby\/microbialthreat.pdf (accessed 2003 Apr 9)."},{"key":"bibr25-aph.1C437","unstructured":"WHO global strategy for containment of antimicrobial resistance, 2001. www.who.int\/emcdocuments\/antimicrobial_resistance\/docs\/EGlobal_Strat.pdf (accessed 2003 Apr 9)."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1C437","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1C437","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1C437","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:07:10Z","timestamp":1777374430000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1C437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["10.1345\/aph.1C437"],"URL":"https:\/\/doi.org\/10.1345\/aph.1c437","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6]]}}}